Advertisement

Clinical Rheumatology

, Volume 33, Issue 9, pp 1355–1357 | Cite as

Efficacy of tocilizumab in a patient with refractory psoriatic arthritis

  • Luisa Costa
  • Francesco Caso
  • Luca Cantarini
  • Antonio Del Puente
  • Raffaele Scarpa
  • Mariangela AttenoEmail author
Case Based Review

Abstract

Psoriatic arthritis (PsA) is an inflammatory arthropathy, associated with skin and/or nail psoriasis and other possible systemic features. In the last years, PsA therapy has been revolutionized by the increasing knowledge in the pathogenetic mechanisms of the disease, involving dysfunction and oversecretion of multiple proinflammatory molecules, in particular tumor necrosis factor (TNF)-α. Hence, therapy of PsA refractory to disease-modifying antirheumatic drugs (DMARDs) relies mainly on the use of anti-TNF-α agents. However, since PsA can often be refractory also to these therapies, use of agents acting on other cytokines, such as interleukin (IL)-1 receptor targeted by anakinra, the IL-12/23 receptor by ustekinumab, the IL-17A by secukinumab, and the IL-6 receptor by tocilizumab, has been reported successfully. Herein we report a case of a refractory PsA patient successfully treated with the IL-6 receptor agent, tocilizumab. A review of the literature on the use of tocilizumab in PsA has been performed.

Keywords

Anti-interleukin-6 receptor (IL-6R) antibody Interleukin-6 (IL-6) Psoriatic arthritis Tocilizumab 

Notes

Disclosures

None.

References

  1. 1.
    Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55–78PubMedCrossRefGoogle Scholar
  2. 2.
    Soscia E, Sirignano C, Catalano O, Atteno M, Costa L, Caso F, Peluso R, Bruner V, Aquino MM, Del Puente A, Salvatore M, Scarpa R (2012) New developments in magnetic resonance imaging of the nail unit. J Rheumatol Suppl 89:49–53PubMedCrossRefGoogle Scholar
  3. 3.
    Scarpa R, Manguso F, D’Arienzo A, D’Armiento FP, Astarita C, Mazzacca G, Ayala F (2000) Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 27:1241–6PubMedGoogle Scholar
  4. 4.
    Costa L, Caso F, D’Elia L, Atteno M, Peluso R, Del Puente A, Strazzullo P, Scarpa R (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31:711–5PubMedCrossRefGoogle Scholar
  5. 5.
    Scarpa R, Altomare G, Marchesoni A, Balato N, Matucci Cerinic M, Lotti T, Olivieri I, Vena GA, Salvarani C, Valesini G, Giannetti A (2010) Psoriatic disease: concepts and implications. J Eur Acad Dermatol Venereol 24:627–630PubMedCrossRefGoogle Scholar
  6. 6.
    Tillett W, de-Vries C, McHugh NJ (2012) Work disability in psoriatic arthritis: a systematic review. Rheumatology (Oxford) 51:275–83CrossRefGoogle Scholar
  7. 7.
    Scarpa R, Costa L, Atteno M, Del Puente A, Caso F, Moll JM (2013) Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opin Pharmacother 14:2311–3PubMedCrossRefGoogle Scholar
  8. 8.
    Atteno M, Costa L, Matarese A, Caso F, Del Puente A, Cantarini L, Bocchino ML, Sanduzzi A, Scarpa R (2014) The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol. doi: 10.1007/s10067-014-2536-z PubMedCentralGoogle Scholar
  9. 9.
    Costa L, Caso F, Atteno M, Giannitti C, Spadaro A, Ramonda R, Vezzù M, Del Puente A, Morisco F, Fiocco U, Galeazzi M, Punzi L, Scarpa R (2014) Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 33:273–6PubMedCrossRefGoogle Scholar
  10. 10.
    Scarpa R, Atteno M, Lubrano E, Provenzano G, D’Angelo S, Spadaro A, Costa L, Olivieri I (2011) The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol 30:1063–7PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Goulabchand R, Mouterde G, Barnetche T, Lukas C, Morel J, Combe B (2014) Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 73:414–9PubMedCrossRefGoogle Scholar
  12. 12.
    Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 29:399–403PubMedCrossRefGoogle Scholar
  13. 13.
    Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P, Ortolan A, Fiocco U, Ramonda R, Punzi L, Scarpa R (2013) Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. doi: 10.1007/s10067-013-2369-1 Google Scholar
  14. 14.
    Fiocco U, Sfriso P, Oliviero F, Roux-Lombard P, Scagliori E, Cozzi L, Lunardi F, Calabrese F, Vezzù M, Dainese S, Molena B, Scanu A, Nardacchione R, Rubaltelli L, Dayer JM, Punzi L (2010) Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint. Arthritis Res Ther 12:R148PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Fiocco U, Sfriso P, Oliviero F, Lunardi F, Calabrese F, Scagliori E, Cozzi L, Di Maggio A, Nardacchione R, Molena B, Felicetti M, Gazzola K, Stramare R, Rubaltelli L, Accordi B, Costa L, Roux-Lombard P, Punzi L, Dayer JM (2013) Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine 80:165–70PubMedCrossRefGoogle Scholar
  16. 16.
    Jung N, Hellmann M, Hoheisel R, Lehmann C, Haase I, Perniok A, Hallek M, Rubbert A (2010) An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 29:1169–73PubMedCrossRefGoogle Scholar
  17. 17.
    Konttinen L, Kankaanpää E, Luosujärvi R, Blåfield H, Vuori K, Hakala M, Rantalaiho V, Savolainen E, Uutela T, Nordström D, ROB-FIN Study Group (2006) Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin Rheumatol 25:882–4PubMedCrossRefGoogle Scholar
  18. 18.
    Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, Wang Y, Noonan L, Brodmerkel C, Song M, Mendelsohn AM, McInnes IB, on behalf of the PSUMMIT-1 and 2 Study Groups (2014) Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. doi: 10.1136/annrheumdis-2013-204741 Google Scholar
  19. 19.
    Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB, on behalf of the PSUMMIT 2 Study Group (2014) Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. doi: 10.1136/annrheumdis-2013-204655 Google Scholar
  20. 20.
    McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK, PSUMMIT 1 Study Group (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780–9PubMedCrossRefGoogle Scholar
  21. 21.
    McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP (2014) Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 73:349–56PubMedCrossRefGoogle Scholar
  22. 22.
    Hughes M, Chinoy H (2013) Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology (Oxford) 52:1728–9CrossRefGoogle Scholar
  23. 23.
    Ogata A, Umegaki N, Katayama I, Kumanogoh A, Tanaka T (2012) Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 79:85–7PubMedCrossRefGoogle Scholar
  24. 24.
    Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, Korendowych E, McHugh N (2012) The ClASsification for Psoriatic ARthritis (CASPAR) criteria—a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 39:154–6PubMedCrossRefGoogle Scholar
  25. 25.
    Fonseca JE, Santos MJ, Canhão H, Choy E (2009) Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 8:538–42PubMedCrossRefGoogle Scholar
  26. 26.
    Fiocco U, Accordi B, Martini V, Oliviero F, Facco M, Cabrelle A, Piva L, Molena B, Caso F, Costa L, Scanu A, Pagnin E, Atteno M, Scarpa R, Basso G, Semenzato G, Punzi L, Doria A, Dayer JM (2014) JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res 58:61–9PubMedCrossRefGoogle Scholar
  27. 27.
    Woodrick RS, Ruderman EM (2012) IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions. Bull Hosp Jt Dis 70:195–9Google Scholar
  28. 28.
    Caso F, Iaccarino L, Bettio S, Ometto F, Costa L, Punzi L, Doria A (2013) Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab. Immunol Res 56:390–7PubMedCrossRefGoogle Scholar
  29. 29.
    Adler S, Kolev M, Varisco PA, Tham M, von Gunten M, Tappeiner C, Villiger PM (2013) Induction of severe systemic lupus erythematosus by TNF blockade and response to anti-IL-6 strategy. J Allergy Clin Immunol 131:1235–7, 1237.e1PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2014

Authors and Affiliations

  • Luisa Costa
    • 1
  • Francesco Caso
    • 2
    • 3
  • Luca Cantarini
    • 3
  • Antonio Del Puente
    • 1
  • Raffaele Scarpa
    • 1
  • Mariangela Atteno
    • 1
    Email author
  1. 1.Rheumatology Unit, Department of Clinical Medicine and SurgeryUniversity Federico IINaplesItaly
  2. 2.Rheumatology Unit, Department of Medicine DIMEDUniversity of PaduaPaduaItaly
  3. 3.Interdepartmental Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Rheumatology Unit, Policlinico Le ScotteUniversity of SienaSienaItaly

Personalised recommendations